|
BRPI0616454A2
(pt)
|
2005-09-30 |
2011-06-21 |
Vitae Pharmaceuticals, Inc. |
métodos de tratamento de cáncer
|
|
US8722710B2
(en)
|
2007-09-26 |
2014-05-13 |
Deuterx, Llc |
Deuterium-enriched pioglitazone
|
|
JP6014155B2
(ja)
|
2011-10-31 |
2016-10-25 |
ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． |
ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
|
|
RU2014121984A
(ru)
|
2011-10-31 |
2015-12-10 |
Ксенон Фармасьютикалз Инк. |
Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
|
|
MX352727B
(es)
|
2011-12-13 |
2017-12-06 |
Dartmouth College |
Tratamiento de trastorno autoinmune al usar agonistas de rxr.
|
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
|
CN104718188B
(zh)
*
|
2012-05-22 |
2018-08-21 |
基因泰克公司 |
N-取代的苯甲酰胺类及其在治疗疼痛中的用途
|
|
KR101663436B1
(ko)
|
2012-07-06 |
2016-10-06 |
제넨테크, 인크. |
N-치환된 벤즈아미드 및 이의 사용 방법
|
|
CA2941562C
(en)
|
2013-03-14 |
2021-09-21 |
Deuterx, Llc |
Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
|
|
RU2015143906A
(ru)
|
2013-03-14 |
2017-04-18 |
Дженентек, Инк. |
Замещенные триазолопиридины и способы их применения
|
|
BR112015023397A2
(pt)
|
2013-03-15 |
2017-07-18 |
Genentech Inc |
benzoxazois substituídos e métodos de uso dos mesmos
|
|
WO2015078374A1
(en)
|
2013-11-27 |
2015-06-04 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
US10188639B2
(en)
|
2014-01-15 |
2019-01-29 |
Deuterx, Llc |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
|
US10328040B2
(en)
|
2014-01-17 |
2019-06-25 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Therapeutic methods
|
|
WO2015187850A2
(en)
*
|
2014-06-03 |
2015-12-10 |
Duke University |
Compounds and methods for treatment of ocular disorders
|
|
JP2017525677A
(ja)
|
2014-07-07 |
2017-09-07 |
ジェネンテック， インコーポレイテッド |
治療用化合物及びその使用方法
|
|
CN104490867A
(zh)
*
|
2014-12-03 |
2015-04-08 |
沈阳药科大学 |
苯甲酸衍生物在制备抗血管新生药物中的用途
|
|
WO2016153949A1
(en)
*
|
2015-03-20 |
2016-09-29 |
Deuterx, Llc |
5-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using same
|
|
HK1252567A1
(zh)
|
2015-05-22 |
2019-05-31 |
基因泰克公司 |
被取代的苯甲酰胺和其使用方法
|
|
AU2016270373A1
(en)
|
2015-06-05 |
2018-01-04 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
|
JP2018526371A
(ja)
|
2015-08-27 |
2018-09-13 |
ジェネンテック， インコーポレイテッド |
治療化合物及びその使用方法
|
|
CA2999769A1
(en)
|
2015-09-28 |
2017-04-06 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
WO2017075607A1
(en)
|
2015-10-31 |
2017-05-04 |
Io Therapeutics, Inc. |
Treatment of nervous system disorders using combinations of pxr agonists and thyroid hormones
|
|
EP3380466A1
(en)
|
2015-11-25 |
2018-10-03 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
CA3016876C
(en)
|
2016-03-10 |
2021-12-28 |
Io Therapeutics, Inc. |
Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
|
|
KR20180121983A
(ko)
*
|
2016-03-10 |
2018-11-09 |
아이오 테라퓨틱스, 인크. |
Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
|
|
EP3436432B1
(en)
|
2016-03-30 |
2021-01-27 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
PE20190980A1
(es)
|
2016-10-17 |
2019-07-09 |
Genentech Inc |
Compuestos terapeuticos y metodos para utilizarlos
|
|
WO2018106641A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles for the treatment of demyelinating diseases
|
|
WO2018106643A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic azoles for the treatment of demyelinating diseases
|
|
WO2018106646A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Aminotriazoles for the treatment of demyelinating diseases
|
|
US10231947B2
(en)
|
2017-01-23 |
2019-03-19 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Isochroman compounds and methods of use thereof
|
|
US10238626B2
(en)
|
2017-01-23 |
2019-03-26 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Therapeutic compounds
|
|
US10238655B2
(en)
|
2017-01-23 |
2019-03-26 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dihydroindene and tetrahydronaphthalene compounds
|
|
CN108434116B
(zh)
*
|
2017-02-16 |
2021-05-11 |
人福普克药业（武汉）有限公司 |
贝萨罗汀软胶囊及其制备方法
|
|
JP2020511511A
(ja)
|
2017-03-24 |
2020-04-16 |
ジェネンテック， インコーポレイテッド |
ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
|
|
US11517549B2
(en)
|
2017-09-20 |
2022-12-06 |
Io Therapeutics, Inc. |
Treatment of disease with esters of selective RXR agonists
|
|
AR114263A1
(es)
|
2018-02-26 |
2020-08-12 |
Genentech Inc |
Compuestos terapéuticos y métodos para utilizarlos
|
|
CA3092682A1
(en)
*
|
2018-03-01 |
2019-09-06 |
DJ Therapeutics LLC |
Bexarotene derivatives and their use in treating cancer
|
|
WO2019168842A1
(en)
|
2018-03-02 |
2019-09-06 |
Oregon Health & Science University |
Amide prodrugs of small molecule nuclear receptor modulators
|
|
US10947251B2
(en)
|
2018-03-30 |
2021-03-16 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
CN113302206A
(zh)
|
2018-11-26 |
2021-08-24 |
戴纳立制药公司 |
治疗脂质代谢失调的方法
|
|
EP3894383A1
(en)
|
2018-12-12 |
2021-10-20 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
|
CA3130371A1
(en)
|
2019-03-01 |
2020-09-10 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
|
KR20220121239A
(ko)
|
2019-11-29 |
2022-08-31 |
아우토반 쎄라퓨틱스, 인크. |
신규한 갑상선 호르몬 모방제
|
|
WO2021257851A1
(en)
|
2020-06-17 |
2021-12-23 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
|
JP7813730B2
(ja)
|
2020-06-17 |
2026-02-13 |
オートバーン セラピューティクス，インク． |
甲状腺様作用剤
|
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
|
MX2024006978A
(es)
|
2021-12-07 |
2024-07-19 |
Io Therapeutics Inc |
Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+.
|
|
CA3242047A1
(en)
|
2021-12-07 |
2023-06-15 |
Io Therapeutics, Inc. |
Use of an rxr agonist in treating drug resistant her2+ cancers
|